Migraine in patients with fibromyalgia and outcomes of greater occipital nerve blockage

Yılmaz, Volkan; Aras, Berke; Ertürk, Fatma Avşar; Çakçı, Fatma Aytül; Umay, Ebru

doi:10.1016/j.clineuro.2019.04.004

Cited by 10 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…103 Other conditions associated with central sensitisation and sympathetic nervous system predominance include temporomandibular disorder, IBS, dyspepsia, RLS, chronic pelvic pain, interstitial cystitis, headache, migraine, chronic fatigue syndrome and vulvodynia all of which present at higher rates in women, and commonly coexist with other conditions from within the same classification. 11,53,[104][105][106][107][108][109] The interplay of genetics and epigenetics relevant to each syndrome adds an additional layer of complexity to the determination of factors that may form a basis for comorbidity. 8,110 Our search terms were crafted to capture the spectrum of FGIDs, yet results did not identify any co-prevalence data capturing the range until 2009, 51 with the exception of functional abdominal pain in two papers (1991 and 1996).…”

Section: Discussionmentioning

confidence: 99%

A systematic review of the association between fibromyalgia and functional gastrointestinal disorders

Erdrich

Hawrelak

Myers

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Fibromyalgia and functional gastrointestinal disorders (FGID) including irritable bowel syndrome (IBS) are common conditions presenting in clinical settings and are more prevalent in women. While the relationship between IBS and fibromyalgia has been demonstrated, a review of the prevalence of the broader group of FGID in adults with fibromyalgia has not been undertaken. The aim of this review was to systematically review the published literature, identifying the comorbidity of FGID in people with fibromyalgia, and to discuss the clinical implications, limitations of current research and areas of interest for future research Methods: Medline, Embase, CINAHL and Web of Science were searched during June 2019. Results were screened for original research articles meeting established criteria for identification of FGID in adults diagnosed with fibromyalgia. Results: A total of 14 studies involving 1340 adults with fibromyalgia, 363 healthy controls and 441 adults with other pathologies were included in this review. Only 1 of the 14 studies included surveyed the full range of FGID . Functional gut disorders were matched to Rome II criteria for reporting and comparison. In addition to increased abdominal pain and functional bloating or gas, IBS of mixed-pattern and constipation-types appear to be more prevalent than diarrhoea-predominant IBS in adults with fibromyalgia. Conclusion: This review confirms previous reports that IBS is common in people living with fibromyalgia and suggests that IBS-mixed and constipation types predominate. An association with a range of FGID other than IBS is suggested, but data are limited. Research exploring the association between fibromyalgia and functional gastrointestinal dysfunction beyond IBS are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review of the association between fibromyalgia and functional gastrointestinal disorders

Erdrich

Hawrelak

Myers

et al. 2020

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…They also found that VAS, MIDAS, and FIQR scores were lower in the third month compared to the first month. They reported that the efficacy of GON blockage was more pronounced in the third month 22 . In our study, we applied PNB to patients with chronic migraine and FM coexistence.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of peripheral nerve blockage on the symptoms of both diseases in patients with fibromyalgia and chronic migraine coexistence

Evcili

Yabalak

2022

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE: Peripheral nerve blockage treatments reduce central sensitization and are effective in patients with migraine. We wanted to evaluate the efficacy of peripheral nerve blockage in patients with fibromyalgia and migraine whose etiology may be responsible for central sensitization, and their associations are common. METHODS: The files of patients with chronic migraine who had peripheral nerve blockage treatment in our clinic and had fibromyalgia were scanned. The patients underwent bilateral great occipital nerve, lesser occipital nerve, and supraorbital nerve blockage at baseline and in the second week. The revised Fibromyalgia Impact Questionnaire, Migraine Disability Assessment Scale, Visual Analog Scale scores, the number of days in pain, and the number of analgesics taken in the last month were recorded. RESULTS: In the third month, Fibromyalgia Impact Questionnaire, Migraine Disability Assessment Scale, and Visual Analog Scale scores were significantly lower from baseline. While Fibromyalgia Impact Questionnaire scores in the third month were significantly lower than in the first month, no significant difference was observed between Visual Analog Scale scores. In the third month, the number of days in pain and the number of analgesics taken in the last month was significantly lower than the baseline but higher than the first month. CONCLUSION: Peripheral nerve blockage has been found to be an effective treatment for the symptoms of both diseases in patients with migraine and fibromyalgia coexistence.

show abstract

“…However, patients with FM were excluded from the PREEMPT trials. Given the high prevalence of FM in CM patients, the lack of studies that evaluate responsiveness to CM treatments, and in particular to OnabotA, in this group of patients is surprising (40). Two Spanish studies that evaluated the effectiveness of OnabotA for CM included FM among other variables in their analysis and reported that FM did not significantly influence the rate of response to OnabotA (36,37).…”

Section: Discussionmentioning

confidence: 99%

“…Patients with FM were excluded from the PREEMPT trials (25,26). Even though FM is a frequent comorbidity in patients with CM and contributes to disability, studies that analyze the response to preventive treatments in this subgroup of patients have been lacking (40). To the best of our knowledge, no studies designed to evaluate the response to OnabotA for CM in patients with FM have been published.…”

Section: Introductionmentioning

confidence: 99%

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia

Real

Terán

2020

Front. Neurol.

View full text Add to dashboard Cite

Introduction: Fibromyalgia (FM) is a frequent comorbidity in patients with chronic migraine (CM). PREEMPT trials, which demonstrated the efficacy of OnabotulinumtoxinA (OnabotA) on CM, excluded patients with FM. Our aim was to evaluate the effectiveness of OnabotA in a series of patients with CM and FM. Methods: We analyzed patients with a previous diagnosis of CM and FM who had received sessions of OnabotA quarterly between January 2014 and January 2020 in a specialized Headache Clinic. Primary endpoint was the reduction in moderate to severe headache days at 3, 6, 9, and 12 months. Results: Data were collected from 31 patients with CM and FM that received OnabotA (100% females). Mean age at first procedure was 50.2 ± 11.3 years. Depression (93.5%), other central sensitization syndromes (irritable bowel syndrome, interstitial cystitis, multiple chemical sensitivity, endometriosis, and chronic fatigue syndrome) (48.4%), and medication overuse headache (90.3%) were frequent comorbidities. 48.4% of patients had failed ≥3 preventives previously. The percentage of patients who achieved ≥30 and ≥50% moderate-severe headache reduction on the third month was 65.4 and 48.2%, respectively. Twenty-three patients completed four cycles of treatment, with 13.4 fewer headache days per month than at baseline (p < 0.001). By 1 year, 69.5% had ≥50% reduction of headache frequency and 39.1% had a ≥75% reduction. In 4 cases (21%), OnabotA was interrupted due to a lack of response. Only mild adverse effects were recorded. Conclusion: OnabotA is an effective treatment for CM in patients with FM.

show abstract

Migraine in patients with fibromyalgia and outcomes of greater occipital nerve blockage

Cited by 10 publications

References 21 publications

A systematic review of the association between fibromyalgia and functional gastrointestinal disorders

A systematic review of the association between fibromyalgia and functional gastrointestinal disorders

Effectiveness of peripheral nerve blockage on the symptoms of both diseases in patients with fibromyalgia and chronic migraine coexistence

OnabotulinumtoxinA Is an Effective Treatment for Chronic Migraine in Patients With Comorbid Fibromyalgia

Contact Info

Product

Resources

About